Non-Invasive Prenatal Testing Market Analysis by Gestation Period (0-12 weeks, 13-24 weeks, 25-36 weeks), by Pregnancy RiskLevel (High & Average Risk, Low Risk), By Region (U.S., UK, Germany, Japan, China, Brazil)And Segment Forecasts, 2014 - 2025

  • ID: 3989831
  • Report
  • Region: Brazil, China, Germany, Japan, United Kingdom, United States, Great Britain
  • 100 pages
  • Grand View Research
1 of 3
The global non-invasive prenatal testing market is anticipated to reach USD 5.5 billion by 2025. Evolution of prenatal testing in the form of noninvasive tests that can serve as an intermediate step between serum screening and invasive diagnostic testing to determine the likelihood of fetal abnormality is expected to drive growth in the reproductive genetics industry over the forecast period.

In addition, presence of payers such as Anthem and Blue Shield of California that have endorsed cfDNA-based Noninvasive Prenatal Testing (NIPT) for trisomies 13, 18, and 21 is expected to impact the adoption rate of these tests, thereby resulting in increased revenue generation.

However, the projected NIPT-related price erosion in this market is expected to continue, thus intensifying competition amongst the operating participants, but restraining revenue generation to a certain extent.

Further Key Findings fromthe Report Suggest:

The market is segmented on the basis of the tests carried out during the gestation period as 0-12 weeks, 13-24 weeks, and 25-36 weeks

13-24 weeks accounted for the largest share owing to the presence of maximum number of the tests carried out in this phase of pregnancy

High & average risk pregnancy held the larger share owing to presence of favorable payer reimbursement in this segment

Rising awareness pertaining to the prevention and screening of chromosomal anomalies, such as Down Syndrome is another factor anticipated to impact adoption

Asia Pacific is expected to register fastest year-on-year progress owing to the gradually increasing average maternal age, & increasing incidence of chromosomal aneuploidies

Some of the key players operating the market space include Natera, Inc;Illumina, Inc; Sequenom; Roche (Ariosa Diagnostics); Quest Diagnostics; and LabCorp

One of the key trends followed by companies includes licensing of the test to other labs and generating significant revenue by collecting royalty payments
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
2 Executive Summary
3 NIPT Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing average maternal age and rising incidence of chromosome syndromes
3.1.1.2 Presence of demand for early and Non-Invasive fetal testing procedure
3.1.1.3 Improvement in the reimbursement scenario
3.1.1.4 Presence of collaborations and licensing agreements
3.1.2 Market restraint analysis
3.1.2.1 Price erosion of the NIPT products
3.1.2.2 Ethical concerns with respect to reproductive genetics
3.2 Penetration & Growth Prospect Mapping, 2015
3.3 Non-Invasive prenatal testing - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter’s
4 NIPT Market: Gestation Duration Estimates & Trend Analysis
4.1 Non-Invasive Prenatal Testing: Gestation Duration Movement Analysis
4.2 0-12 weeks
4.2.1 Global NIPT 0-12 weeks, 2014 - 2025 (USD Million)
4.3 13-24 weeks
4.3.1 Global NIPT 13-24 weeks, 2014 - 2025 (USD Million)
4.4 25-36 weeks
4.4.1 Global NIPT 25-36 weeks, 2014 - 2025 (USD Million)
5 NIPT Market: Risk Type Estimates & Trend Analysis
5.1 Non-Invasive Prenatal Testing: Risk Type Movement Analysis
5.2 High & Average Risk
5.2.1 Global high & average risk NIPT market, 2013 - 2025 (USD Million)
5.3 Low Risk
5.3.1 Global low risk NIPT market, 2013 - 2025 (USD Million)
6 NIPT Market: Regional Estimates & Trend Analysis, by Gestation Period & Risk Type
6.1 Non-Invasive Prenatal Testing Share By Region, 2015 & 2025
6.2 North America
6.2.1 North America Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S Non-Invasive prenatal testing culture market, 2013 - 2025 (USD Million)
6.2.3 Canada.
6.2.3.1 Canada Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
6.3.2 Germany.
6.3.2.1 Germany Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
6.3.3 UK
6.3.3.1 UK Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
6.4 Asia Pacific.
6.4.1 Asia Pacific Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
6.4.2 China
6.4.2.1 China Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
6.4.3 Japan
6.4.3.1 Japan Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
6.5 Latin America.
6.5.1 Latin America Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
6.6 Middle East & Africa.
6.6.1 Middle East & Africa Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
7 Competitive Landscape
7.1 Strategy framework
7.2 Market participation categorization
7.2.1 Natera Inc.
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.3 Product benchmarking
7.2.1.4 Strategic initiatives
7.2.2 Illumina Inc. (Verinata Health, Inc.)
7.2.2.1 Company overview
7.2.2.2 Financial performance
7.2.2.3 Product benchmarking
7.2.2.4 Strategic initiatives
7.2.3 Sequenom Laboratories
7.2.3.1 Company overview
7.2.3.2 Financial performance
7.2.3.3 Product benchmarking
7.2.3.4 Strategic initiatives
7.2.4 Laboratory Corporation of America Holdings
7.2.4.1 Company overview
7.2.4.1 Financial Performance
7.2.4.2 Product benchmarking
7.2.4.3 Strategic initiatives
7.2.5 Quest Diagnostics
7.2.5.1 Company overview
7.2.5.2 Financial performance
7.2.5.3 Product benchmarking
7.2.5.4 Strategic initiatives
7.2.6 F. Hoffmann-La Roche Ltd (Ariosa Diagnostics)
7.2.6.1 Company overview
7.2.6.2 Financial performance
7.2.6.3 Product benchmarking
7.2.6.4 Strategic initiatives
7.2.7 BGI Diagnosis
7.2.7.1 Company overview
7.2.7.2 Financial performance
7.2.7.3 Product benchmarking
7.2.7.4 Strategic initiatives
7.2.8 LifeCodexx AG
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Product benchmarking
7.2.8.4 Strategic initiatives
7.2.9 Berry Genomics Co. Ltd.
7.2.9.1 Company overview
7.2.9.2 Financial performance
7.2.9.3 Product benchmarking
7.2.9.4 Strategic initiatives

List of Tables

Table 1 North America Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
Table 2 North America Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
Table 3 North America Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
Table 4 North America Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
Table 5 U.S. Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
Table 6 U.S. Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
Table 7 U.S. Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
Table 8 U.S. Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
Table 9 Canada Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
Table 10 Canada Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
Table 11 Canada Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
Table 12 Canada Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
Table 13 Europe Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
Table 14 Europe Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
Table 15 Europe Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
Table 16 Europe Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
Table 17 Germany Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
Table 18 Germany Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
Table 19 Germany Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
Table 20 Germany Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
Table 21 UK Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
Table 22 UK Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
Table 23 UK Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
Table 24 UK Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
Table 25 Asia Pacific Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
Table 26 Asia Pacific Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
Table 27 Asia Pacific Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
Table 28 Asia Pacific Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
Table 29 China Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
Table 30 China Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
Table 31 China Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
Table 32 China Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
Table 33 Japan Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
Table 34 Japan Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
Table 35 Japan Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
Table 36 Japan Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
Table 37 Latin America Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
Table 38 Latin America Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
Table 39 Latin America Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
Table 40 Latin America Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
Table 41 Brazil Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
Table 42 Brazil Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
Table 43 Brazil Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
Table 44 Brazil Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
Table 45 MEA Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
Table 46 MEA Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
Table 47 MEA Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
Table 48 MEA Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)
Table 49 South Africa Non-Invasive prenatal testing estimates, by gestation period, 2014 & 2015 (USD Million)
Table 50 South Africa Non-Invasive prenatal testing forecasts, by gestation period, 2016 - 2025 (USD Million)
Table 51 South Africa Non-Invasive prenatal testing estimates, by risk type, 2014 & 2015 (USD Million)
Table 52 South Africa Non-Invasive prenatal testing forecasts, by risk type 2016 - 2025 (USD Million)

List of Figures

Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value chain based sizing & forecasting
Figure 6 QFD modelling for market share assessment
Figure 7 Market summary
Figure 8 Market trends & outlook
Figure 9 Market segmentation & scope
Figure 10 Market driver relevance analysis (Current & future impact)
Figure 11 Market restraint relevance analysis (Current & future impact)
Figure 12 Penetration & growth prospect mapping, 2015
Figure 13 SWOT Analysis, By Factor (political & legal, economic and technological)
Figure 14 Porter’s Five Forces Analysis
Figure 15 Non-Invasive prenatal testing: Gestation duration outlook key takeaways
Figure 16 Non-Invasive prenatal testing: Gestation duration movement analysis
Figure 17 Global Non-Invasive prenatal testing in 0-12 weeks, 2014 - 2025 (USD Million)
Figure 18 Global Non-Invasive prenatal testing in 13-24 weeks, 2014 - 2025 (USD Million)
Figure 19 Global Non-Invasive prenatal testing in 25-36 weeks, 2014 - 2025 (USD Million)
Figure 20 Non-Invasive prenatal testing: Risk type outlook key takeaways
Figure 21 Global Non-Invasive prenatal testing: Risk type movement analysis
Figure 22 Global high & average risk NIPT market, 2013 - 2025 (USD Million)
Figure 23 Global low risk NIPT market, 2013 - 2025 (USD Million)
Figure 24 Regional market place: Key takeaway
Figure 25 Non-Invasive prenatal testing regional outlook, 2015 & 2024
Figure 26 North America Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
Figure 27 U.S Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
Figure 28 Canada Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
Figure 29 Europe Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
Figure 30 Germany Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
Figure 31 UK Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
Figure 32 Asia Pacific Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
Figure 33 China Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
Figure 34 Japan Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
Figure 35 Latin America Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
Figure 36 Brazil Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
Figure 37 Middle East & Africa Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
Figure 38 South Africa Non-Invasive prenatal testing, 2013 - 2025 (USD Million)
Figure 39 Strategy framework
Figure 40 Participant categorization
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll